The Prevention Options for Women Evaluation Research (POWER) Cohort

University of Washington

Status: Completed

Conditions: HIV/AIDS

Treatments: Drug: Truvada

Study type: Observational

Funder types: Other; Other U.S. Federal agency; NIH

Identifiers

NCT03490058

STUDY00000950

R01MH114544 (U.S. NIH Grant/Contract)

AID-OAA-A-15-00034 (Other Grant/Funding Number)

Details and patient eligibility

About

The POWER Cohort study is a PrEP implementation project to demonstrate Pre-exposure prophylaxis (PrEP) delivery for young women in Cape Town and Johannesburg, South Africa and Kisumu, Kenya.

Full description

PrEP will be delivered to young women according to emerging national guidelines in family planning clinics (Kisumu, Kenya), youth friendly clinics (Johannesburg, South Africa), and mobile youth friendly clinics (Cape Town, South Africa). The investigators will evaluate PrEP delivery and follow cohorts of young women at each clinic location to understand PrEP uptake and use. In the Kisumu clinics, the investigators will also offer expedited partner therapy and partner HIV self-tests to women who test positive for chlamydia and/or gonorrhea. At one clinic in Johannesburg, the investigators will evaluate the use of a decision support tool to improve the decision to initiate PrEP.

Enrollment: 2,255 patients

Sex: Female

Ages: 16 to 25 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Age 16-25 (16 and 17 year olds, where permissible by national regulations and local IRB approval)
• Able and willing to provide written informed consent
• Recently sexually active (defined as having had vaginal intercourse at least once in the previous three months)
• HIV uninfected based on negative HIV rapid tests, on the date of enrollment

Trial design

2,255 participants in 1 patient group

Young women

Description:

Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.

Treatment:

Drug: Truvada